Photo of Rong Chen

Rong Chen

  • ASSISTANT PROFESSOR Genetics and Genomic Sciences
Print ProfilePrint Profile


  • B.S., University of Science and Technology of China

  • M.S., Shanghai Institute of Organic Chemistry

  • Ph.D., Boston University


    Dr. Chen is Director of Clinical Genome Informatics at Icahn Institute of Genetics and Multiscale Biology. His research focuses on developing databases, genome repositories, and clinical applications to interpret personal genomes for clinical diagnosis, precision medicine, predictive disease risk, and novel therapeutics.

    Prior to Mount Sinai, he led the collaborative efforts at Stanford University to drive personalized medicine and clinical diagnosis on Mendelian and complex diseases using genome and exome sequencing. Dr. Chen also helped launch a startup company Personalis, which won the VA's contract for the Million Veteran Genome project.

    Dr. Chen has a broad interest in translational bioinformatics and genome interpretation, and has published over 60 papers in Lancet, Cell, Nature Biotechnology, Nature Methods, PNAS, AJHG, PLoS Genetics, PLoS Computational Biology, Genome Research, Genome Biology, Genome Medicine, AJT, and Proteins. He holds numerous patents for software and databases on personalized medicine, diagnosis, and structure modeling.

    Chen Laboratory


  • 2011 -
    ICHG Young Investigator Awards
    International Congress of Human Genetics


My research focuses on translational bioinformatics and genome interpretation. We have been building hundreds of databases from mining literature and public repositories, and integrating genomic, genetic, phenotypic, clinical, and environmental data to illustrate disease mechanisms, identify diagnostics biomarkers, and drive personalized medicine. For more about informatics, please check Chen Laboratory.

To view a complete list of publications, please click here.


Hsu I, Chen R, Ramesh A, Corona E, Kang HP, Ruau D, Butte AJ. Systematic identification of DNA variants associated with ultraviolet radiation using a novel Geographic-Wide Association Study (GeoWAS). BMC medical genetics 2013; 14.

Chen R, Corona E, Sikora M, Dudley JT, Morgan AA, Moreno-Estrada A, Nilsen GB, Ruau D, Lincoln SE, Bustamante CD, Butte AJ. Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases. PLoS genetics 2012; 8(4).

Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, Dudley JT, Ormond KE, Pavlovic A, Morgan AA, Pushkarev D, Neff NF, Hudgins L, Gong L, Hodges LM, Berlin DS, Thorn CF, Sangkuhl K, Hebert JM, Woon M, Sagreiya H, Whaley R, Knowles JW, Chou MF, Thakuria JV, Rosenbaum AM, Zaranek AW, Church GM, Greely HT, Quake SR, Altman RB. Clinical assessment incorporating a personal genome. Lancet 2010 May; 375(9725).

Chen R, Sigdel TK, Li L, Kambham N, Dudley JT, Hsieh SC, Klassen RB, Chen A, Caohuu T, Morgan AA, Valantine HA, Khush KK, Sarwal MM, Butte AJ. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS computational biology 2010; 6(9).

Chen R, Davydov EV, Sirota M, Butte AJ. Non-synonymous and synonymous coding SNPs show similar likelihood and effect size of human disease association. PloS one 2010; 5(10).

Chen R, Mallelwar R, Thosar A, Venkatasubrahmanyam S, Butte AJ. GeneChaser: identifying all biological and clinical conditions in which genes of interest are differentially expressed. BMC bioinformatics 2008; 9.

Chen R, Li L, Butte AJ. AILUN: reannotating gene expression data automatically. Nature methods 2007 Nov; 4(11).

Chen R, Weng Z. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins 2002 May; 47(3).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Chen during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Scientific Advisory Board:

  • Bina Technologies

Royalty Payments:

  • Accelrys; Personalis

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Personalis

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


1255 Fifth Avenue Floor 1st floor Room 112
New York, NY 10029